Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Leases (2019 - 2025)

RedHill Biopharma has reported Current Leases over the past 7 years, most recently at $900000.0 for Q4 2025.

  • Quarterly Current Leases rose 154.96% to $900000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $900000.0 through Dec 2025, up 154.96% year-over-year, with the annual reading at $900000.0 for FY2025, 154.96% up from the prior year.
  • Current Leases was $900000.0 for Q4 2025 at RedHill Biopharma, up from $214000.0 in the prior quarter.
  • Over five years, Current Leases peaked at $7.2 million in Q1 2022 and troughed at $214000.0 in Q2 2025.
  • The 5-year median for Current Leases is $2.8 million (2021), against an average of $3.2 million.
  • Year-over-year, Current Leases plummeted 88.86% in 2023 and then surged 154.96% in 2025.
  • A 5-year view of Current Leases shows it stood at $2.6 million in 2021, then skyrocketed by 150.31% to $6.4 million in 2022, then plummeted by 88.86% to $718000.0 in 2023, then tumbled by 50.84% to $353000.0 in 2024, then surged by 154.96% to $900000.0 in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Current Leases are $900000.0 (Q4 2025), $214000.0 (Q2 2025), and $353000.0 (Q4 2024).